Literature DB >> 6098039

Disorders associated with purine and pyrimidine metabolism.

N L Edwards, I H Fox.   

Abstract

There has been an explosion of knowledge in disorders of purine and pyrimidine metabolism during the last 20 years. During this time, more than 10 diseases have been discovered and their metabolic bases studied. Hyperuricemia and gout remain the most common clinical disorder. Rarely these disorders are explainable by an inherited enzyme abnormally, such as hypoxanthine-guanine phosphoribosyltransferase deficiency, phosphoribosyl-pyrophosphate synthetase deficiency, or glucose-6-phosphatase deficiency. The description of immunodeficiency syndromes in association with purine enzyme deficiency has led to a novel area of investigation encompassing the biochemical basis for immune function. Although less information is available concerning the other diseases associated with renal calculi, myopathy, anemia, and central nervous system dysfunction, further research will elucidate important metabolic relationships. These will no doubt expand our understanding of the pathogenesis of these disorders and provide innovative therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6098039

Source DB:  PubMed          Journal:  Spec Top Endocrinol Metab        ISSN: 0193-0982


  3 in total

1.  A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Authors:  Leah C Jimmerson; Lane R Bushman; Michelle L Ray; Peter L Anderson; Jennifer J Kiser
Journal:  Pharm Res       Date:  2016-09-15       Impact factor: 4.200

2.  Purification, characterization, and gene cloning of purine nucleosidase from Ochrobactrum anthropi.

Authors:  J Ogawa; S Takeda; S X Xie; H Hatanaka; T Ashikari; T Amachi; S Shimizu
Journal:  Appl Environ Microbiol       Date:  2001-04       Impact factor: 4.792

3.  A Three-mRNA Signature Associated with Pyrimidine Metabolism for Prognosis of BRCA.

Authors:  Xiaoxue Zhang; Qiang Zhang; Xianxin Xie; Yang Li; Zhiyuan Pang; Tao Yu
Journal:  Biomed Res Int       Date:  2022-02-16       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.